Published in Am J Gastroenterol on March 15, 2011
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut (2013) 1.37
Treatment of IBD: where we are and where we are going. Am J Gastroenterol (2014) 1.02
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res (2014) 0.88
IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol (2015) 0.86
Electrochemiluminescence immunoassay method underestimates cortisol suppression in ulcerative colitis patients treated with oral prednisone. World J Gastroenterol (2014) 0.83
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci (2013) 0.82
In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis (2014) 0.82
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol (2015) 0.80
The antiprotozoal drug pentamidine ameliorates experimentally induced acute colitis in mice. J Neuroinflammation (2012) 0.79
A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation. FEBS J (2016) 0.79
Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J (2014) 0.78
Enhanced production of early lineages of monocytic and granulocytic cells in mice with colitis. Proc Natl Acad Sci U S A (2012) 0.78
Amelioration of experimental colitis after short-term therapy with glucocorticoid and its relationship to the induction of different regulatory markers. Immunology (2016) 0.77
Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma. Therap Adv Gastroenterol (2013) 0.77
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol (2015) 0.77
Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother (2016) 0.77
A phase II study of laquinimod in Crohn's disease. Gut (2014) 0.76
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol (2016) 0.75
High-resolution Quantitative Computed Tomography Demonstrates Structural Defects in Cortical and Trabecular Bone in IBD Patients. J Crohns Colitis (2016) 0.75
Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol (2015) 0.75
Steroid-sparing strategies in the management of ulcerative colitis: efficacy of leukocytapheresis. World J Gastroenterol (2012) 0.75
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA (2006) 6.26
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med (2003) 5.15
How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc (2008) 4.58
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology (2010) 3.87
Functional Dyspepsia. N Engl J Med (2015) 3.66
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol (2010) 2.97
Gastro-oesophageal reflux disease. Lancet (2006) 2.96
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med (2006) 2.94
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol (2003) 2.83
Immune activation in patients with irritable bowel syndrome. Gastroenterology (2007) 2.82
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol (2003) 2.63
Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ (2007) 2.60
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Design of treatment trials for functional gastrointestinal disorders. Gastroenterology (2006) 2.58
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol (2007) 2.46
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut (2006) 2.43
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol (2009) 2.36
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol (2011) 2.32
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol (2008) 2.28
G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology (2004) 2.24
Minimizing postcolonoscopy abdominal pain by using CO(2) insufflation: a prospective, randomized, double blind, controlled trial evaluating a new commercially available CO(2) delivery system. Gastrointest Endosc (2002) 2.24
Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol (2009) 2.22
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology (2011) 2.22
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology (2009) 2.19
Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol (2013) 2.18
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis (2009) 2.15
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol (2005) 2.13
Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2012) 2.09
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol (2009) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Risks of proton-pump inhibitors: what every doctor should know. Med J Aust (2009) 2.03
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study. Gastroenterology (2010) 2.01
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Does Helicobacter pylori really cause duodenal ulcers? Yes. BMJ (2009) 2.01
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
Prevalence of faecal incontinence and associated risk factors; an underdiagnosed problem in the Australian community? Med J Aust (2002) 2.00
Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr (2011) 1.96
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology (2002) 1.94